Publication Date:
2012-10-19
Description:
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer Oncogene 31, 4559 (18 October 2012). doi:10.1038/onc.2011.539 Authors: E S Ratner, F K Keane, R Lindner, R A Tassi, T Paranjape, M Glasgow, S Nallur, Y Deng, L Lu, L Steele, S Sand, R-U Muller, E Bignotti, S Bellone, M Boeke, X Yao, S Pecorelli, A Ravaggi, D Katsaros, D Zelterman, M C Cristea, H Yu, T J Rutherford, J N Weitzel, S L Neuhausen, P E Schwartz, F J Slack, A D Santin & J B Weidhaas
Keywords:
platinum resistanceKRAS variantovarian canceroutcome
Print ISSN:
0950-9232
Topics:
Medicine
Permalink